Dendritic cells are immune cells that collect pieces of material from their surroundings and show them to T cells, and the signals they give at that moment help decide whether a T cell is switched on or held back. Counting them in a tumour sample does not show that they have taught T cells to recognise the cancer.
Dendritic cells acquire material from their surroundings or make antigen themselves, process proteins and display fragments on HLA molecules, where a matching T-cell receptor can recognise a peptide and HLA pair. Cross-presentation is the route that places acquired material on class I, and class II presentation, usually of acquired proteins to CD4 T cells, is a separate route. They are a family of subsets with overlapping jobs. Conventional type 1 cells (cDC1) are particularly important for cross-presentation: mice lacking the transcription factor Batf3 lost CD8-alpha-positive dendritic cells, their dendritic cells were defective in cross-presentation, and they rejected highly immunogenic tumours less well (Hildner et al., 2008). Human CD141-positive dendritic cells, activated with poly I:C, cross-presented soluble antigen and antigen from necrotic virus-infected cells better than CD1c-positive cells (Jongbloed et al., 2010). Conventional type 2 cells are usually studied for class II presentation to CD4 T cells, and plasmacytoid cells for type I interferon responses. In a review, plasmacytoid cells are described as producing large amounts of interferon alpha, while the contribution of CD11b-positive conventional cells to CD4 T-cell priming in vivo was still described as to be determined (Merad et al., 2013). The same review describes conventional cells as inducing immunity to foreign antigens and enforcing tolerance to self-antigens, and migration-linked maturation as raising MHC class II and costimulatory molecules, with cytokine production added when migration follows inflammation. In mice, antigen delivered to dendritic cells in the steady state led to brief T-cell activation followed by loss and unresponsiveness of the T cells, and adding an anti-CD40 antibody changed the outcome to prolonged activation (Hawiger et al., 2001). For conventional type 2 cells, a review of dendritic cells in T-cell programming reported that they were most often found to be required for CD4 T-cell priming in mice, with T helper 1 differentiation as an exception in which type 1 cells were often required, and noted that type 2 cells can be difficult to distinguish from monocyte-derived cells because markers overlap (Eisenbarth, 2019); another review said that specific depletion of type 2 cells was still needed to confirm their unique role in priming CD4 T cells (Durai and Murphy, 2016). Single-cell sequencing of human blood found six dendritic-cell and four monocyte subtypes, including a population that resembles plasmacytoid cells but potently activates T cells, so one positive marker is weaker evidence than a supported subset assignment (Villani et al., 2017).
Showing the technology this term belongs to: Dendritic cell vaccines.
Shares NK cell, Immune system, T cell.
Shares NK cell, Immune system, T cell.
Shares Dendritic-cell cross-presentation (cDC1), Antigen presentation & immune editing.
Shares Immune system, T cell, Antigen presentation & immune editing.
Shares Immune system, T cell.
Shares Pattern recognition: DAMPs and PAMPs, Dendritic-cell cross-presentation (cDC1), Antigen presentation & immune editing.
Shares Pattern recognition: DAMPs and PAMPs, Dendritic-cell cross-presentation (cDC1).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/